RNS Number:6057U
Protherics PLC
26 January 2004


                 PROTHERICS ANNOUNCES FIRST NAMED PATIENT SALES
                            FOR VORAXAZE(TM) IN EUROPE

Protherics PLC ("Protherics"), the international biopharmaceuticals company,
today announced its first named patient sales in Europe of Voraxaze, its
treatment for patients at risk of kidney damage from methotrexate toxicity. In
Europe, medical practitioners are able to request and purchase certain
un-licensed drugs on a named patient basis where there is unmet clinical need.
IDIS has been appointed as the global distributor of Voraxaze for named patient
sales (excluding the US).

Protherics plans to submit licensing applications for Voraxaze to the US and
European authorities during the first half of the next financial year. Named
patient sales in Europe provide Protherics with additional clinical data to
support its licensing applications for Voraxaze. With orphan drug status
recently granted in both Europe and the US, the company is hopeful of an
expedited review. Following regulatory approvals, Protherics anticipates that
Voraxaze will be launched in the US in the first half of 2005 with a launch in
Europe following in the second half.

Initially Voraxaze will be indicated for patients with, or at risk of, kidney
damage from the toxic effects of methotrexate, a widely used chemotherapeutic
agent. Clinical trials have shown that the early use of Voraxaze to treat
methotrexate toxicity can reduce deaths from kidney failure. The market
potential for Voraxaze, when used as a rescue therapy in patients with impaired
kidney function, is estimated to be $200 million. In the future, a much bigger
opportunity exists for Voraxaze use in combination with methotrexate in all
patients on high-dose methotrexate treatment to optimize therapy.

Andrew Heath, Chief Executive of Protherics said:

"Voraxaze is becoming widely available in Europe as hospitals establish their
purchasing procedures. Our next goal is to gain regulatory approval in the US
and Europe to allow us to realise the full potential of this life saving
product."

Methotrexate

Methotrexate is a widely used anti-cancer drug. Its non-mutagenic properties
make it particularly suited for use in younger patients. However, particularly
when used in high doses for certain types of cancer, methotrexate can result in
reduced kidney function. This further delays the elimination of methotrexate
from the body leading to mucositis, reduced platelet and white blood cell
counts, and ultimately death.

Voraxaze

Voraxaze is a recombinant enzyme (carboxypeptidase G2) which acts by rapidly
reducing dangerously elevated serum methotrexate levels.

Voraxaze has been tested in over 200 cancer patients treated with methotrexate
in Europe and the US. No serious side effects have been observed.

                                      ENDS
For further information contact:
Protherics PLC                        +44 (0) 20 7246 9950
Andrew Heath, Chief Executive         +44 (0) 7919 480510 (mobile)
Nick Staples, Corporate Affairs       +44 (0) 20 7246 9950

The Maitland Consultancy              +44 (0) 20 7379 5151
Brian Hudspith/ Michelle Jeffery

Protherics PLC

Protherics PLC was formed in September 1999 from the merger of Proteus
International plc and Therapeutic Antibodies Inc. Protherics is an international
biopharmaceutical company, engaged in the development, production and
commercialisation of immunopharmaceuticals and cancer therapies.

The Company's ordinary shares are listed on the Official List of the UK Listing
Authority and are traded on the London Stock Exchange. (PTI.L)

An electronic version of this will be available at: www.protherics.com

This release, and oral statements made from time to time by Company
representatives concerning the subject matter hereof, may contain so-called
"forward looking statements". These statements can be identified by introductory
words such as "expects", "plans", "will", "estimates", "forecasts", "projects",
words of similar meaning, and by the fact that they do not relate strictly to
historical or current facts. Forward-looking statements frequently are
discussing the Company's growth strategy, operating and financial goals, plans
relating to regulatory submissions and approvals and development programs. Many
factors may cause actual results to differ from the Company's forward-looking
statements, including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not. Those and
other risks are described in the Company's filings with the Securities and
Exchange Commission, copies of which are available from the SEC or may be
obtained upon request from the Company. No forward-looking statement is a
guarantee of future results or events, and one should avoid placing undue
reliance on such statements.






                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCBJMFTMMATBTI